Quick Answer
REPLIGEN CORP reported Cash and Equivalents of $566.02 million for fiscal year 2025.
REPLIGEN CORP Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $566.02M | -25.3% |
| 2024 | $757.36M | +0.8% |
| 2023 | $751.32M | +43.5% |
| 2022 | $523.46M | -13.3% |
| 2021 | $603.81M | -15.8% |
| 2020 | $717.29M | +35.7% |
| 2019 | $528.39M | +172.6% |
| 2018 | $193.82M | +11.5% |
| 2017 | $173.76M | +42.2% |
| 2016 | $122.23M | +126.0% |
| 2015 | $54.09M | +53.0% |
| 2014 | $35.36M | -11.2% |
| 2013 | $39.83M | +36.4% |
| 2012 | $29.21M | +161.6% |
| 2011 | $11.17M | -21.4% |
| 2011 | $14.20M | +45.0% |
| 2010 | $9.79M | -21.8% |
| 2010 | $12.53M | +148.5% |
| 2009 | $5.04M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $748.75M | -4.5% | +5.6% |
| June 30, 2025 | $708.86M | -12.4% | +1.7% |
| March 31, 2025 | $697.23M | -10.7% | -7.9% |
| December 31, 2024 | $757.36M | +0.8% | -3.4% |
| September 30, 2024 | $783.96M | +24.3% | -3.1% |
| June 30, 2024 | $809.15M | +34.0% | +3.7% |
| March 31, 2024 | $780.62M | +51.1% | +3.9% |
| December 31, 2023 | $751.32M | +43.5% | +19.1% |
- REPLIGEN CORP showed a decrease of -25.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, REPLIGEN CORP’s cash and equivalents has grown by 11127.4% (from $5.04 million to $566.02 million).
- The most recent figure is from REPLIGEN CORP’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: